Singapore Annie Tan highlights the strategy she laid out to navigate the BMS Singapore, Thailand and Malaysia affiliates through the COVID-19 pandemic; the opportunities and challenges of integrating the Celgene portfolio into local BMS operations; and her aim to build the company into an oncology and haematology powerhouse in Southeast Asia…
Switzerland Dr Remo Gujer gives an overview of the BMS footprint in Switzerland and Austria, the ongoing integration of legacy Celgene operations, market access challenges, clinical trials, and the importance of digitalisation. There is so much healthcare data available today but not enough is being collected or used in an…
Romania With the 2019 acquisition of Celgene – one of the largest pharma acquisition in history – two of the sector’s most innovative oncology companies have joined forces to lead the charge against cancer. The combined entity is expected to rise in the global biopharma rankings, complete with a fresh new…
Talent Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have moved on to new roles in their ever-expanding careers. LATAM Expertise Pedro Galvis Mexico is an interesting mix…
USA The bestselling drugs of 2018 in the USD 485 billion US pharma market. The list features several major blockbusters benefiting from the delays in biosimilar approval in the US, as well as several small-molecule medications that stand to lose out to generic competition in the coming years. AbbVie’s Humira is…
Top 10 The Top 10 bestselling orphan drugs in the USA in 2017. Celgene’s Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion, followed by Roche’s Rituxan (rituximab) with USD 4.2 billion in sales and TEVA’s Copaxone (glatiramer acetate) with USD 3.1 billion. The most expensive drug in…
Top 10 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American firm, Celgene. Made with Visme Infographic Maker
Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…
Canada Stefan Larson, CEO of Northern Biologics, explains the major milestones for Northern Biologics over the past three years, his personal motivation for starting a biotech company, their collaboration with Celgene, and his thoughts on the strengths and areas for growth within the Canadian biotech industry. Stefan, three years into the…
Brazil Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in Brazil, as well as the company’s willingness to cope with the country’s unpredictability while establishing its operation in Brazil. Celgene…
Pharma Pasquale Frega, General Manager for Celgene Italy, discusses the company’s rapid growth and imminent entry into immunology, the business and regulatory environment for innovators in the country and the characteristics of the Italian market that make it especially promising to Celgene. Mr. Frega, to start off, Imnovid, Celgene’s newest oral treatment…
Pharma Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help to tackle the current difficulties in accessing the Dutch market, while implementing new innovative pricing models such as pay for benefit.…
See our Cookie Privacy Policy Here